Format

Send to

Choose Destination
See comment in PubMed Commons below
Lancet. 2002 Mar 23;359(9311):1033-4.

Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia.

Author information

  • 1Service d'Hématologie-Oncologie, Centre de Recherche, Hôpital Sainte-Justine, 3175 Côte Ste-Catherine, Quebec H3T 1C5, Montreal, Canada. maja.krajinovic@umontreal.ca

Abstract

Interindividual variability in response to methotrexate could be caused by variable concentrations of thymidylate synthase. We investigated the possible association between a tandem-repeat polymorphism in the thymidylate synthase promoter, of which a triple repeat is associated with increased expression of thymidylate synthase, and outcome of acute lymphoblastic leukaemia in 205 children treated with methotrexate. We obtained DNA samples from buccal epithelial cells, peripheral blood, or bone marrow in remission, and analysed them for the polymorphism by PCR amplification. Individuals who were homozygous for the triple repeat had a poorer outlook than those with other genotypes (odds ratio 4.1, 95% CI 1.9-9.0, p=0.001). Genotyping of thymidylate synthase might make it possible to individualize treatment for patients with acute lymphoblastic leukaemia.

PMID:
11937185
DOI:
10.1016/S0140-6736(02)08065-0
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center